EcoDrugPlus

Ribosomal Protein L3

Ensembl ID : ENSDARG00000003599
Gene Symbol: RPL3
12 Enzyme and pathways 5 Cross references
338 Possible Orthologues:

Ribosomal Protein L30

Ensembl ID : ENSDARG00000035871
Gene Symbol: RPL30
12 Enzyme and pathways 5 Cross references
317 Possible Orthologues:

Ribosomal Protein L31

Ensembl ID : ENSDARG00000053365
Gene Symbol: RPL31
12 Enzyme and pathways 5 Cross references
650 Possible Orthologues:

Ribosomal Protein L34

Ensembl ID : ENSDARG00000029500
Gene Symbol: RPL34
12 Enzyme and pathways 5 Cross references
364 Possible Orthologues:

Ribosomal Protein L35

Ensembl ID : ENSDARG00000018334
Gene Symbol: RPL35
12 Enzyme and pathways 5 Cross references
260 Possible Orthologues:

Ribosomal Protein L35a

Ensembl ID : ENSDARG00000088030
Gene Symbol: RPL35A
12 Enzyme and pathways 5 Cross references
512 Possible Orthologues:

Ribosomal Protein L36

Ensembl ID : ENSDARG00000100588
Gene Symbol: RPL36
12 Enzyme and pathways 5 Cross references
398 Possible Orthologues:

Ribosomal Protein L37

Ensembl ID : ENSDARG00000034291
Gene Symbol: RPL37
5 Cross references
428 Possible Orthologues:

Ribosomal Protein L38

Ensembl ID : ENSDARG00000006413
Gene Symbol: RPL38
12 Enzyme and pathways 5 Cross references
234 Possible Orthologues:

Ribosomal Protein L39

Ensembl ID : ENSDARG00000036316
Gene Symbol: RPL39
12 Enzyme and pathways 5 Cross references
542 Possible Orthologues:

Ribosomal Protein L4

Ensembl ID : ENSDARG00000041182
Gene Symbol: RPL4
12 Enzyme and pathways 5 Cross references
341 Possible Orthologues:

Ribosomal Protein L5a

Ensembl ID : ENSDARG00000020197
Gene Symbol: RPL5A
5 Cross references
447 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).